Infectious Diseases is a vast therapeutic area. Despite these obvious global challenges, solutions appear to be on the decline. Whilst global patent applications for new antibiotics halved between 2004 and 2013, only two antibiotics NMEs were registered with the FDA between 2008 and 2012, down from 16 in the past 30 years.

So what is jamming the infectious diseases drug development machine? Is it related to the processes that detect and monitor pathogenic activities which may then impact on lab innovations especially on resistance activity? Could it be linked to the antibiotic/antiviral business models that don’t seem to be adaptable to these new global challenges?

This Leadership Seminar will explore these questions with contributions from industry experts who are confronted by these challenges. Speakers include Auspherix CSO, Dr Richard Rutter who will be presenting latest research conducted in collaboration with scientists at Domainex.  Senior Medicinal Chemist, Jonathan Powell will also be attending the event.

Further information on our collaboration with Auspherix can be viewed in this case study.